Mesenchymal stem/stromal cells: dedicator to maintain tumor homeostasis DOI

J Yao,

Li Sun, Feng Gao

et al.

Human Cell, Journal Year: 2024, Volume and Issue: 38(1)

Published: Nov. 28, 2024

Language: Английский

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition DOI Creative Commons
Antonino Glaviano,

Hannah Lau,

Lukas M. Carter

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 13, 2025

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.

Language: Английский

Citations

16
Endothelial cell in tumor angiogenesis: Origins, mechanisms, and therapeutic implication DOI Creative Commons

Yulong Han,

Binqiang Zhu,

Shu Meng

et al.

Genes & Diseases, Journal Year: 2025, Volume and Issue: unknown, P. 101611 - 101611

Published: March 1, 2025

Language: Английский

Citations

0
Natural products‐based antiangiogenic agents: New frontiers in cancer therapy DOI Creative Commons
Tiago Azevedo, Tiago Ferreira, Sheila I. Peña‐Corona

et al.

Food Frontiers, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 1, 2024

Abstract Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides comprehensive overview of natural product‐based therapies, focusing on molecular mechanisms therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega‐3 fatty acids, polysaccharides, proteins, carotenoids, were investigated their properties. Challenges such dose standardization, routes administration, side effects remain. Further studies, in‐depth animal models human epidemiological must elucidate clinical efficacy safety. Synergistic current bevacizumab tyrosine kinase inhibitors, should be explored. Additionally, the hormone‐dependent like genistein highlight need safety evaluation. In conclusion, products hold promise adjunctive therapies conventional antineoplastic drugs modulating angiogenesis cancer. However, robust trials are needed validate preclinical findings ensure efficacy.

Language: Английский

Citations

2
GDF11 inhibits the malignant progression of hepatocellular carcinoma via regulation of the mTORC1‑autophagy axis DOI Open Access

Qingyi Wu,

Chan Fan,

Kebo Liu

et al.

Experimental and Therapeutic Medicine, Journal Year: 2024, Volume and Issue: 27(6)

Published: April 15, 2024

Hepatocellular carcinoma (HCC) is a common malignant tumor, which associated with poor prognosis and high mortality rate. It well known that growth differentiation factor 11 (GDF11) acts as tumor suppressor in various types of cancer, including HCC. The present study aimed to determine the tumor-suppressive properties GDF11 HCC assess intrinsic mechanisms. In study, human hepatoma cell line Huh-7 was transfected overexpression plasmid (Oe-GDF11) for gain-of-function experiments investigate effects on biological behaviors cells, proliferation, colony formation, apoptosis, cycle arrest, migration, invasion, epithelial-mesenchymal transition (EMT) angiogenesis. cycle, invasion angiogenesis cells were assessed by CCK-8, EdU staining, flow cytometry, wound healing, Transwell tube formation assays, respectively. Apoptosis-, cycle-, EMT-related key factors also determined western blot assay. Furthermore, Oe-GDF11-transfected treated mammalian target rapamycin (mTOR) activator MHY1485 rescue explore whether could exert antitumor against via mediating mTOR complex 1 (mTORC1)-autophagy axis. verified be lowly expressed cells. Overexpression inhibited EMT facilitated apoptosis arrest Additionally, it inactivated mTORC1 signaling pathway enhance autophagy Treatment partially reversed conclusion, may through inactivating strengthen autophagy.

Language: Английский

Citations

1
Discovery of novel amide derivatives against VEGFR-2/tubulin with potent antitumor and antiangiogenic activity DOI

Zhenling Liu,

S.-Y. Mao,

Huixia Li

et al.

Bioorganic Chemistry, Journal Year: 2024, Volume and Issue: 151, P. 107679 - 107679

Published: July 27, 2024

Language: Английский

Citations

1
Design, synthesis and biological evaluation of indazole derivatives as VEGFR-2 kinase inhibitors with anti-angiogenic properties DOI

Haoyu Zha,

Feilong Li,

Li Cai

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 279, P. 116889 - 116889

Published: Sept. 19, 2024

Language: Английский

Citations

0
Mesenchymal stem/stromal cells: dedicator to maintain tumor homeostasis DOI

J Yao,

Li Sun, Feng Gao

et al.

Human Cell, Journal Year: 2024, Volume and Issue: 38(1)

Published: Nov. 28, 2024

Language: Английский

Citations

0